Imène Hadji, Medical Oncologist and OncoDaily Algeria Hub Lead, shared on LinkedIn:
“JIPO at ESMO 2026: upper GI cancers, with Dr. Haeseong Park.
It was a pleasure to speak with Dr. Haeseong Park, GI Oncologist and Phase I Clinical Investigator at Dana-Farber Cancer Instituter, at ESMO – European Society for Medical Oncology 2026 about where gastroesophageal cancer is heading.
Highlights from our conversation:
- Recent advances: the past few years have brought several successful first-line therapies in gastroesophageal cancer. At ESMO 2026, Dr. Park pointed to the HERIZON-GEA-01 interim analysis of zanidatamab (a HER2-targeted agent), which supports another first-line option for HER2-positive gastroesophageal adenocarcinoma. Dr. Park is also looking forward to the Claudin 18.2 antibody-drug conjugate data from CLARITY-Gastric 01.
- Many targets, one question: HER2, Claudin 18.2 and other targets each cover a small share of patients, and they overlap. That is exciting, but it makes sequencing after first-line progression harder.
- Biomarkers: in practice we test PD-L1, HER2, Claudin 18.2 and microsatellite status. Others, such as MET and KRAS amplification, may also matter, and future trials should study them beyond the first line, including the perioperative setting.
- The challenge: which biomarker matters most for an individual patient? Dr. Park would like to see a large platform study with predictive modelling to match each patient with the best treatment, though it would need substantial resources.
- A message to young oncologists: despite recent progress, life expectancy after diagnosis is still around a couple of years, which Dr. Park calls unacceptable. Clinical research in GI oncology can make a real difference, and the next generation is welcome.
Thank you, Dr. Park, for your time and your insights.
Watch the full interview.”
About Haeseong Park
Dr. Haeseong Park is a gastrointestinal medical oncologist and clinical investigator at Dana-Farber Cancer Institute in Boston, where he also serves as an Associate Professor of Medicine at Harvard Medical School.
His work focuses on gastrointestinal cancers, particularly stomach, esophageal and gastroesophageal cancers. He is involved in early-stage clinical research, exploring new treatment options such as targeted therapies and immunotherapy.
At Dana-Farber, Dr. Park works on clinical trials aimed at bringing promising treatments to patients. His research also looks at new therapeutic targets, treatment resistance and ways to improve outcomes for people with gastrointestinal cancers.
You may also be interested in: